Healthcare

Private health insurer Medibank has not released a Deloitte report into last year’s cyberattack that exposed the private information of 10 million customers.

A class action has been filed on behalf of 25 people whose loved ones died during a COVID-19 outbreak at the Newmarch House in Sydney.

Bayer told a jury that clinical trials from the 1990’s to 2014 showed its Essure birth control device was “safe and efficacious”, as the pharmaceutical giant faces trial in a class action by patients who claim they suffered debilitating injuries from the device.

Pharmaceutical giant Bayer cannot write off debilitating chronic pain and bleeding which patients allegedly experienced after being implanted with Essure contraceptives as “common women’s symptoms”, a court has heard in the first day of trial in a long-running class action.

Shine Lawyers can deduct 50 per cent of its fees and all of its costs from a $300 million settlement in pelvic mesh class actions against Johnson & Johnson while a judge mulls whether the law firm’s total bill is fair and reasonable.

A bid to drop a class action against Philips Electronics over recalled sleep apnea machines showed a gap in access to justice that was “very hard to fill” given the high cost of bringing large scale litigation, a judge has said.

Boutique law firm Barry Nilsson has snagged a Norton Rose Fulbright disputes partner who specialises in healthcare product liability class actions and his five-member team to join its Sydney office. 

Australia’s largest private health insurer Medibank has been hit with a shareholder class action in the wake of a massive cyberattack that left the data of 10 million customers exposed.

A unit of Purdue Pharma has fired off a cross-claim in Australian drug maker AUPharma’s lawsuit alleging the US drug giant was wrongly granted patent extensions for oxycodone products marketed as Targin.

Beauty giant McPherson’s has denied ASIC’s claims that it misled the market and breached its disclosure obligations in 2020, arguing that a document showing sales of its Dr LeWinn’s line were down by $21 million was a draft that couldn’t have been used to revise a financial forecast.